This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2013 Jul;12(7):492-3.

doi: 10.1038/nrd4067.

First-in-class insomnia drug on the brink of approval nod

PMID: 23812257
DOI: 10.1038/nrd4067

First-in-class insomnia drug on the brink of approval nod

Randy Osborne. Nat Rev Drug Discov. 2013 Jul.

. 2013 Jul;12(7):492-3.

doi: 10.1038/nrd4067.

Author

PMID: 23812257
DOI: 10.1038/nrd4067

No abstract available

PubMed Disclaimer

Similar articles

Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Herring WJ, et al. Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28. Neurology. 2012. PMID: 23197752 Clinical Trial.
Suvorexant: something new for sleep?
Reddy A, Puvvada SC, Kommisetti S, El-Mallakh RS, Lippmann S. Reddy A, et al. Acta Neuropsychiatr. 2015 Feb;27(1):53-5. doi: 10.1017/neu.2014.31. Epub 2014 Nov 14. Acta Neuropsychiatr. 2015. PMID: 25397996
Suvorexant for the treatment of insomnia.
Jacobson LH, Callander GE, Hoyer D. Jacobson LH, et al. Expert Rev Clin Pharmacol. 2014 Nov;7(6):711-30. doi: 10.1586/17512433.2014.966813. Expert Rev Clin Pharmacol. 2014. PMID: 25318834 Review.
[Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
Tanaka Y, Aoki I, Ishine T, Renger JJ, Winrow CJ, Hisada S. Tanaka Y, et al. Nihon Yakurigaku Zasshi. 2016 Jul;148(1):46-56. doi: 10.1254/fpj.148.46. Nihon Yakurigaku Zasshi. 2016. PMID: 27430679 Review. Japanese. No abstract available.
New class of sleep drugs may offer a safer night's rest.
Willyard C. Willyard C. Nat Med. 2012 Jul 6;18(7):996. doi: 10.1038/nm0712-996. Nat Med. 2012. PMID: 22772537 No abstract available.

See all similar articles

Cited by

Insomnia and hypertension: A misty landscape.
Stavropoulos K, Imprialos KP, Doumas M, Karagiannis A, Papademetriou V. Stavropoulos K, et al. J Clin Hypertens (Greenwich). 2019 Jun;21(6):835-837. doi: 10.1111/jch.13519. Epub 2019 Mar 15. J Clin Hypertens (Greenwich). 2019. PMID: 30874341 Free PMC article. No abstract available.
Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.
Summers CH, Yaeger JDW, Staton CD, Arendt DH, Summers TR. Summers CH, et al. Brain Res. 2020 Mar 15;1731:146085. doi: 10.1016/j.brainres.2018.12.036. Epub 2018 Dec 24. Brain Res. 2020. PMID: 30590027 Free PMC article. Review.
Suvorexant, a dual orexin receptor antagonist for the management of insomnia.
Bennett T, Bray D, Neville MW. Bennett T, et al. P T. 2014 Apr;39(4):264-6. P T. 2014. PMID: 24757363 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information